A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1150 participants.
Also called NCT05171049
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,150 participants
- Registry
-
NCT05171049
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Austria, Canada, China, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Latvia, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05171049. Randomized; single masking; primary purpose treatment. Start 2022-05-05 (actual); primary completion 2026-02-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Acronym
- ASTER
- Condition
- Venous Thromboembolism
- Condition
- Deep Venous Thrombosis
- Condition
- Pulmonary Embolism
- Intervention (Biological)
- Abelacimab
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Anthos Therapeutics, Inc.
- Collaborator
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05171049- Content hash
736283419e02e467e8a6bb3e44ca0cc2ddf9678fd0412fafc0d0e65f532fdaa5